No Eli Lilly-specific events occurred this period. The only matched event was smart ring maker Oura postponing its $2.2 billion IPO, which has no connection to Lilly's business.
No Eli Lilly-specific events occurred this period. The only matched event was the IPO development of smart ring maker Oura, which has no connection to Lilly's business.
No Eli Lilly-specific events occurred this period. The only matched event was a macro market development involving Fed rate-hike signals and rising Treasury yields, with no direct business impact on Lilly.
Eli Lilly advanced on both the deal-making and R&D infrastructure fronts this period. The company signed a research collaboration and exclusive license agreement with a subsidiary of China's InnoCare Pharma worth up to $3.25 billion, covering multiple novel drug targets. Separately, Lilly's TuneLab platform partnered with several biotech firms, reflecting an industry shift in AI drug discovery competition from models to closed-loop infrastructure.
Eli Lilly saw developments on two fronts this period. On one hand, China's 15th Five-Year Plan designated biomedicine as a national pillar industry, driving a surge in Hong Kong biotech stocks, a policy tailwind that indirectly benefits Lilly as a global pharma leader. On the other, Lilly and Novo Nordisk face dozens of US lawsuits alleging their GLP-1 drugs caused a rare vision-loss condition, with cases consolidated into multidistrict litigation.
Only one indirectly relevant event was detected this period: Eli Lilly's competitor Novo Nordisk saw its shares fall 5.4% after its 2030 strategic plan failed to impress investors at a Capital Markets Day. The event does not involve Eli Lilly directly, but reflects shifting dynamics in the weight-loss drug competitive landscape. No new developments directly involving Eli Lilly were observed.
Smart ring maker Oura has postponed its initial public offering (IPO) citing market uncertainty, according to multiple reports. The decision comes despite reports that the offering was about four times oversubscribed. The company had planned to list on the Nasdaq under the ticker OURA, offering 50 million shares at $40-$44 each, with a fully diluted valuation of approximately $14.9 billion. No new timeline was provided.
Smart ring maker Oura launched its US IPO roadshow on September 21, 2026, targeting a fully diluted valuation of $15.62 billion. The company and existing shareholders plan to raise up to $2.2 billion by selling 50 million shares at $40-$44 each. The offering is approximately 4x oversubscribed, defying recent market volatility and IPO delays. Oura will list on Nasdaq under ticker "OURA," with pricing set for September 29.
On Thursday, U.S. stocks closed mixed as the Dow fell for a third consecutive session. The 30-year Treasury yield surged to 5.502%, its highest since 2004, and the 10-year yield reached 5.223%, a level not seen since 2007. Multiple Federal Reserve officials, including Philadelphia Fed President Paulson and New York Fed President Williams, signaled that further rate hikes may be needed. Oil prices rose sharply amid Middle East tensions, with Brent crude gaining 3.41% to $106.60 per barrel. Meta shares jumped 4.5% after its AI assistant Muse became the top-downloaded app.
InnoCare Pharma announced on September 24 that its wholly-owned subsidiary, Beijing InnoCare Pharma Tech, signed a research collaboration and exclusive license agreement with Eli Lilly. The deal covers up to five novel drug targets addressing unmet clinical needs. Eli Lilly will pay up to $100 million in upfront and near-term milestones, with potential development and commercialization milestone payments totaling approximately $3.25 billion. InnoCare is also entitled to tiered single-digit percentage royalties on net sales. The news reversed earlier share declines, with A-shares turning positive and H-shares narrowing losses.
Major technology companies including Anthropic and ByteDance are intensifying their push into AI-driven drug development, shifting focus from model capabilities to building complete "data-model-experiment-data" closed-loop systems. Anthropic has built a wet lab in San Francisco, while ByteDance's Anew Labs secured $290 million in external funding. Eli Lilly's Lilly TuneLab partnered with GenScript, Twist Bioscience, and Ginkgo Bioworks. Industry executives argue the key barrier is now systemic infrastructure, not just AI models, though clinical success rates remain unproven.
On September 21, 2026, Hong Kong-listed innovative drug stocks surged, with the CSI Hong Kong Innovative Drug Index rising over 5%. The rally was driven by China’s “15th Five-Year Plan for Pharmaceutical Industry Development,” issued by ten ministries on September 18, which designates biomedicine as a national pillar industry and targets over 20% annual growth for innovative drugs by 2030. Additional catalysts included the NMPA’s approval of the world’s first AI EEG brain-computer interface medical device standard, positive Phase III data from Chinese drugs at the 2026 World Lung Cancer Conference, and record out-licensing deals exceeding $120 billion year-to-date.
Dozens of US patients have filed lawsuits against Novo Nordisk and Eli Lilly, alleging their GLP-1 drugs semaglutide and tirzepatide caused non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can lead to blindness. Over 90 lawsuits have been filed in New Jersey state court, with cases consolidated into multidistrict litigation MDL 3163 in Pennsylvania federal court. The European Medicines Agency classified NAION as a "very rare" side effect of semaglutide in June 2025. Novo Nordisk denies a causal link, citing its own trial data.
Novo Nordisk (now Novo) saw its stock fall 5.4% on Monday after unveiling its 2030 strategic ambitions at a Capital Markets Day in London. The company targets launching more than five multi-blockbuster drugs by 2030 and reaching 150 billion Danish kroner ($23 billion) in risk-adjusted pipeline sales by 2035. CEO Mike Doustdar acknowledged semaglutide patent expirations beginning in the U.S. in 2032. Analysts expressed disappointment, with Jacob Pedersen calling the growth benchmark "lower ambition" and Per Hansen saying investors had hoped for a transformative announcement that does not exist.
Danish pharmaceutical giant Novo Nordisk has partnered with AI company Anthropic to use its Claude Science platform for drug discovery and development. The collaboration aims to accelerate R&D workflows, address complex biological challenges, and shorten drug development timelines for chronic diseases. Novo Nordisk CEO Mike Doustdar stated the company aims to become the world's most AI-driven healthcare company. The partnership follows Novo Nordisk's earlier collaborations with OpenAI and Amazon, and Anthropic's prior agreement with Bristol-Myers Squibb.
Chinese equities closed slightly lower on September 17, with the Shanghai Composite falling 0.36%. Innovative drug and auto stocks surged after GenScript partnered with Eli Lilly’s AI drug platform and GAC Group announced a FAW equity acquisition. Huawei moved up its Ascend 960 chip release to Q1 2027. The Federal Reserve raised rates by 25 basis points to 3.75%-4.00%, the first hike since July 2023.
Chinese stock markets closed slightly lower on September 17, with the Shanghai Composite falling 0.36%, the Shenzhen Component dropping 0.29%, and the ChiNext Index declining 0.12%. Combined half-day turnover reached 1.24 trillion yuan. Innovative drug and CXO stocks surged after GenScript Biotech announced a collaboration with Eli Lilly's AI drug discovery platform. The automotive sector rose on GAC Group's planned equity acquisition from FAW, while agriculture stocks gained on a government digital village plan. The Federal Reserve raised interest rates by 25 basis points.
Chinese stock markets closed slightly lower on September 17, with the Shanghai Composite Index falling 0.36%, the Shenzhen Component Index dropping 0.29%, and the ChiNext Index declining 0.12%. Half-day turnover reached 1.24 trillion yuan, up 79.5 billion yuan. Innovative drug and CXO stocks surged after GenScript Biotech announced a collaboration with Eli Lilly’s AI drug discovery platform. The automotive sector rose after GAC Group’s equity acquisition plan from FAW. Agriculture stocks gained on a digital village plan. Precious metals fell.
Eli Lilly released Phase 3 data for retatrutide, a triple-hormone agonist, and mid-stage results for its combination drug EloraTTZP (eloralintide + tirzepatide). Retatrutide helped patients with Type 2 diabetes lose up to 60 pounds (23% body weight), the largest weight loss recorded in a diabetes drug trial. EloraTZP delivered greater weight loss and A1C reduction than tirzepatide alone. The drugs are described as a potential “new high-water mark” and “Godzilla” of weight-loss treatments.
IllustrationSmart ring maker Oura has postponed its initial public offering, citing market uncertainty. The decision comes despite reports that the IPO was about four times oversubscribed, with cornerstone investors Eli Lilly and Dragoneer committing $400 million. The company had planned to list on Nasdaq under the ticker OURA, offering 50 million shares at $40-$44 each, targeting a valuation of up to $14.9 billion. No new timeline has been provided.
Reference imageSmart ring maker Oura launched its US IPO roadshow on September 21, 2026, targeting a fully diluted valuation of $15.62 billion. The offering of 50 million shares at $40-$44 each aims to raise up to $2.2 billion. The IPO has received approximately 4x oversubscription, with pricing set for September 29 and trading on Nasdaq under ticker "OURA." Eli Lilly and Dragoneer have indicated interest in purchasing up to $100 million and $300 million of shares respectively. Oura reported $1.21 billion in revenue for the nine months ended June 30, a 74% year-over-year increase.
Reference imageChina's innovative drug stocks surged in September 2026, driven by the release of the 15th Five-Year Plan for the pharmaceutical industry, which targets over 20% annual growth for the sector by 2030. The rally was further boosted by positive Phase III clinical data from Chinese firms at the World Lung Cancer Conference, record out-licensing deals exceeding $120 billion, and regulatory pledges to support innovation and overseas expansion. Hong Kong-listed biotech ETFs rose over 5% on September 21.
Reference imageTech giants including Anthropic and ByteDance are moving beyond AI model development to build physical wet labs and complete experimental loops. Anthropic has built a wet lab in San Francisco, while ByteDance's AI drug unit Anew Labs raised $290 million. Industry executives argue the competitive focus has shifted from model capabilities to building systematic infrastructure integrating data, models, and real-world experiments. However, clinical success rates and return on investment remain unproven.
IllustrationOn September 25, Hong Kong's three major indices fell amid Fed rate hike expectations and closed southbound trading. The Hang Seng Index dropped 1.01%, the Hang Seng Tech Index fell 1.13%, and the Hang Seng China Enterprises Index lost 1.21%, with total turnover at HKD 102.2 billion. Despite the weak market, New Gonow RV surged 22.64% in late trading, bringing its year-to-date gain to over 10x, boosted by a 10-department Chinese government policy to promote RV consumption. Biotech stocks rose, with Genscript Biotech up 8.05% after announcing a wet-lab partnership with Eli Lilly's AIDD platform. Lenovo Group gained 3.16%, up over 300% YTD.
Reference imageOver 90 US lawsuits have been filed since 2025 against Novo Nordisk and Eli Lilly, alleging their GLP-1 drugs semaglutide and tirzepatide caused non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can lead to permanent blindness. Novo Nordisk disputes the claims, citing a large randomized controlled trial that found no increased NAION risk. Eli Lilly says it will continue reviewing data. Regulatory warnings have been added in Europe, the UK, Japan, Australia, and New Zealand.
IllustrationUS Treasury yields surged to multi-decade highs on September 24, with the 30-year yield reaching 5.502% (highest since 2004) and the 10-year yield hitting 5.223% (highest since 2007). The selloff intensified as multiple Federal Reserve officials, including New York Fed President John Williams and Philadelphia Fed President Anna Paulson, signaled another rate hike this year is likely. The CME FedWatch tool showed a 71% probability of an October rate increase. Oil prices rose over 3% amid Middle East tensions, while Oracle shares fell 3.47% after issuing a force majeure notice on a New Mexico data center project.
IllustrationInnoCare Pharma announced on September 24 that its subsidiary signed a licensing agreement with Eli Lilly to discover and develop up to five drug targets. The deal has a potential value of up to $3.35 billion, including $100 million in upfront and near-term payments, up to $3.25 billion in milestone payments, and tiered royalties. InnoCare's stock fell over 10% after the announcement, reflecting investor concerns over the low upfront payment and long-term milestone uncertainty.
IllustrationOn September 21, 2026, Novo Nordisk held its Capital Markets Day in London, unveiling a 2030 strategy to launch over five blockbuster drugs and achieve over $23 billion in pipeline sales by 2035. The market reacted sharply, with shares falling up to 8% in US and European trading, as investors were disappointed by the lack of short-term catalysts and the company's projection of 2026-2030 revenue growth in line with industry peers. CEO Mike Doustdar acknowledged the looming patent cliff for semaglutide in 2032 and the need to rebuild investor trust. The company also disclosed 13,000 job cuts from restructuring.
IllustrationOn September 22, Chinese A-share markets closed mixed with the Shanghai Composite up 0.06% and turnover reaching 2.14 trillion yuan. AI application stocks surged after Meta's Muse AI agent topped Apple's free app chart, driving Meta's stock up 11% overnight. CPU concept stocks rallied on expectations of increased server demand from AI agent deployment, though gains narrowed. The pharmaceutical sector rose on Moderna's mRNA cancer therapy news. Over 3,000 stocks declined amid rapid sector rotation.
IllustrationNovo Nordisk has partnered with Anthropic to integrate its Claude AI models, including Claude Science, into drug discovery and development workflows. The collaboration aims to accelerate R&D, automate clinical-trial report generation, and address complex biological challenges. Novo Nordisk CEO Mike Doustdar stated the company aims to become the world's "most AI-driven healthcare company." Financial terms and specific drug targets were not disclosed. The partnership expands Novo's existing AI collaborations with OpenAI and Amazon Web Services.
Reference imageEli Lilly CEO Dave Ricks announced that Foundayo now accounts for one in three new oral weight-loss drug starts in the US, with market share growing weekly. The company broke ground on a $6.5 billion manufacturing facility in Houston, Texas, expected to be operational by 2030. Foundayo generated $98 million in second-quarter revenue since its April US launch. The drug competes with Novo Nordisk’s Wegovy pill, and Lilly held about 61% of the overall weight-loss and diabetes market in the second quarter.
Reference imageChinese equities closed slightly lower on September 17, with the Shanghai Composite falling 0.36%. Sector rotation was rapid: innovative drug and CXO stocks surged after GenScript Biotech announced a collaboration with Eli Lilly's AI drug discovery platform. The automotive sector rose on GAC Group's plan to acquire equity from FAW. Agriculture stocks gained on a government digital village plan. Huawei announced its Ascend 960 chip release is moved up to Q1 2027. The Federal Reserve raised interest rates by 25 basis points to 3.75%-4.00%.
Reference imageNovartis announced its experimental drug pelacarsen, developed with Ionis Pharmaceuticals, failed to significantly improve cardiovascular outcomes in a Phase 3 trial involving 8,323 patients, despite successfully lowering Lp(a) levels. The failure triggered a sector-wide selloff, with Novartis shares falling 14%, Amgen 10%, and Eli Lilly 2%. Analysts say the Lp(a) hypothesis is weakened but not disproven, raising uncertainty for rival drugs from Amgen and Eli Lilly.
Illustration